Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2014 (2014), Article ID 802473, 3 pages
http://dx.doi.org/10.1155/2014/802473
Case Report

Teriparatide Induced Delayed Persistent Hypercalcemia

1Internal Medicine Residency, Fairview/Cleveland Clinic Foundation, Cleveland, OH 44111, USA
2Department of Hospital Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA

Received 13 June 2014; Revised 5 August 2014; Accepted 5 August 2014; Published 18 August 2014

Academic Editor: Michael P. Kane

Copyright © 2014 Nirosshan Thiruchelvam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Augustine and M. J. Horwitz, “Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis,” Current Osteoporosis Reports, vol. 11, no. 4, pp. 400–406, 2013. View at Google Scholar
  2. E. S. Christenson, X. Jiang, R. Kagan, and P. F. Schnatz, “Osteoporosis management in post-menopausal women,” Minerva Ginecologica, vol. 64, no. 3, pp. 181–194, 2012. View at Google Scholar · View at Scopus
  3. G. Mazziotti, A. Angeli, J. P. Bilezikian, E. Canalis, and A. Giustina, “Glucocorticoid-induced osteoporosis: an update,” Trends in Endocrinology & Metabolism, vol. 17, no. 4, pp. 144–149, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Migliaccio, G. Resmini, A. Buffa et al., “Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): a multicenter observational real life study,” Clinical Cases in Mineral and Bone Metabolism, vol. 10, no. 1, pp. 56–60, 2013. View at Google Scholar · View at Scopus
  5. J. H. Krege, E. Glass, D. Donley et al., “Teriparatide treatment was not associated with predosehypercalcemia in treatment-naive women with osteporosois,” Endocrine Society, New Orleans, La, USA, Program & Abstracts ENDO 2004.
  6. Eli Lilly and Company, 2012, http://pi.lilly.com/us/forteo-pi.pdf.
  7. A. C. Looker, E. S. Orwoll, C. C. Johnston Jr. et al., “Prevalence of low femoral bone density in older U.S. adults from NHANES III,” Journal of Bone and Mineral Research, vol. 12, no. 11, pp. 1761–1768, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Canalis, A. Giustina, and J. P. Bilezikian, “Mechanisms of anabolic therapies for osteoporosis,” The New England Journal of Medicine, vol. 357, no. 9, pp. 950–916, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. D. T. Gold, B. S. Pantos, D. N. Masica, D. A. Misurski, and R. Marcus, “Initial experience with teriparatide in the United States,” Current Medical Research and Opinion, vol. 22, no. 4, pp. 703–708, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Hajime, Y. Okada, H. Mori, and Y. Tanaka, “A case of teriparatide-induced severe hypophosphatemia and hypercalcemia,” Journal of Bone and Mineral Metabolism, 2014. View at Publisher · View at Google Scholar
  11. C. Karatoprak, K. Kayatas, H. Kilicaslan et al., “Severe hypercalcemia due to teriparatide,” Indian Journal of Pharmacology, vol. 44, no. 2, pp. 270–271, 2012. View at Publisher · View at Google Scholar · View at Scopus